The UK BioIndustry Association has welcomed the government's decision to set up an Office for Life Sciences. The biotechnology manufacturer's group stated that "the establishment of OLS is a positive and much-needed development and a new way for government and industry to work collaboratively to secure the future of what should be one of the UK's most promising sectors."
Recently, the BIA had highlighted the capital challenges that the UK life sciences sector faces in the current economic situation and called for swift government action "to reinvigorate the investment environment" for small- and medium-sized enterprises (Marketletter April 6). The BIA believes that the OLS is the mechanism to deliver results, provided it can do so rapidly.
Many of the required initiatives were outlined in the Bioscience Innovation and Growth Team's Review and Refresh of Bioscience 2015, published in January. These include:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze